We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blocking the Acsl14 Enzyme Prevents Ferroptosis-Linked Cell Death

By Gerald M. Slutzky, PhD
Posted on 25 Nov 2016
Print article
Image: A fibroblast undergoing ferroptosis (Photo courtesy of Helmholtz Zentrum München).
Image: A fibroblast undergoing ferroptosis (Photo courtesy of Helmholtz Zentrum München).
Inhibiting the enzyme Acsl4 (acyl-CoA synthetase long-chain family member 4), which is involved in fatty acid metabolism, has been postulated to be a viable therapeutic approach to preventing ferroptosis-related diseases.

Ferroptosis, a poorly understood form of programmed cell death, has been implicated in the pathological cell death found in neuronal and kidney tissues. It may also be possible to selectively trigger ferroptosis in certain cancer cells. Previously, only a few essential molecules, such as glutathione peroxidase 4 (Gpx4), have been implicated in the ferroptotic process.

Investigators at Helmholtz Zentrum München (Germany) applied two independent approaches - a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines - to generate new details as to how ferroptosis works.

They reported in the November 14, 2016, online edition of the journal Nature Chemical Biology that ACSL4 was as an essential component for ferroptosis execution. Specifically, cells in which the genes for both Gpx4 and Acsl4 proteins had been removed showed marked resistance to ferroptosis. Mechanistically, Acsl4 enriched cellular membranes with long polyunsaturated omega-6 fatty acids. Targeting Acsl4 with thiazolidinediones, a class of antidiabetic compound, prevented tissue destruction in a mouse model of ferroptosis, Moreover, Acsl4 was preferentially expressed in a panel of basal-like breast cancer cell lines and predicted their sensitivity to ferroptosis.

"The individual mechanisms involved in this type of cell death remain only partly understood, and our findings make an important contribution towards a better understanding of ferroptotic cell death," said senior author Dr. Marcus Conrad, head of a research group at the institute of developmental genetics at the Helmholtz Zentrum München. "Our intriguing insights that the Acsl4 enzyme plays a substantial role in the process of cell death provide novel cues for yet-unrecognized therapeutic approaches towards inhibiting ferroptosis in degenerative diseases or inducing ferroptosis in certain tumor diseases. In particular, tumors that are otherwise very difficult to treat with standard chemotherapy might be amenable for ferroptosis therapy."

Related Links:
Helmholtz Zentrum München

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more